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Background:Treatment guidelines recommend the use of
peginterferon alfa-2b or peginterferon alfa-2a in combination
with ribavirin for chronic hepatitis C virus (HCV) infection.
However, these regimens have not been adequately compared.
Methods:At 118 sites, patients who had HCV genotype 1 infec-
tion and who had not previously been treated were randomly
assigned to undergo 48 weeks of treatment with one of three
regimens: peginterferon alfa-2b at a standard dose of
1.5 microg per kilogram of body weight per week or a low dose
of 1.0 microg per kilogram per week, plus ribavirin at a dose of
800 to 1400 mg per day, or peginterferon alfa-2a at a dose of
180 microg per week plus ribavirin at a dose of 1000 to
1200 mg per day. We compared the rate of sustained virologic
response and the safety and adverse-event proﬁles between
the peginterferon alfa-2b regimens and between the standard-
dose peginterferon alfa-2b regimen and the peginterferon
alfa-2a regimen.
Results:Among 3070 patients, rates of sustained virologic
response were similar among the regimens: 39.8% with stan-
dard-dose peginterferon alfa-2b, 38.0% with low-dose peginter-
feron alfa-2b, and 40.9% with peginterferon alfa-2a (P = 0.20
for standard-dose vs. low-dose peginterferon alfa-2b; P = 0.57
for standard-dose peginterferon alfa-2b vs. peginterferon alfa-
2a). Estimated differences in response rates were 1.8% (95%
conﬁdence interval [CI, 2.3 to 6.0) between standard-dose
and low-dose peginterferon alfa-2b and 1.1% (95% CI, 5.3
to 3.0) between standard-dose peginterferon alfa-2b and pegin-
terferon alfa-2a. Relapse rates were 23.5% (95% CI, 19.9 to 27.2)
for standard-dose peginterferon alfa-2b, 20.0% (95% CI, 16.4 to
23.6) for low-dose peginterferon alfa-2b, and 31.5% (95% CI,
27.9 to 35.2) for peginterferon alfa-2a. The safety proﬁle was
similar among the three groups; serious adverse events wereJournal of Hepatology 20
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sustained virologic response was achieved in 86.2% and 78.7%,
respectively.
Conclusions: In patients infected with HCV genotype 1, the
rates of sustained virologic response and tolerability did not
differ signiﬁcantly between the two available peginterferon–
ribavirin regimens or between the two doses of peginterferon
alfa-2b. (ClinicalTrials.gov No. NCT00081770) 2009 Massachu-
setts Medical Society.
 2009 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Which pegylated IFN treatment is the best to cure chronic hepatitis
C? This long-debated question should have been ﬁnally answered
by the IDEAL [1], the ﬁrst large randomized study comparing
head-to-head PEG IFN alfa-2a and alfa-2b combined with ribavirin
(RBV). Taken at face value, these treatments are an even match:
both PEGs bring home about 40% of sustained virological response
(SVR) in patients infected with HCV genotype 1. Perhaps the more
disturbing ﬁnding is that for PEG IFN alfa-2b the registered dosage
of 1.5 lg/kg/wk is in excess, since 1 lg will obtain a comparable
rate of SVR. Hence, for many years we might have over-treated
patients, a practice that in real-life conditions often translates into
reduced patient adherence and ultimately in reduced effectiveness.
In 2001 PEG IFN alfa-2b was approved by the FDA and then by
the EMEA on the basis of the Manns study [2]. It was felt that the
trial design, although showing superiority to the 1.5 lg vs. the
0.5 lg dose, did not indicate whether an intermediate dose would
be sufﬁcient. The issue was further clouded by the range of RBV
doses used, even if a post-hoc analysis suggested higher SVR at
an exposure to RBV beyond 13 mg/kg body weight/day. In the
US, the latter ﬁnding was translated into a recommended dose
for RBV ranging between 800 and 1400 mg/day [3]. The lack of
information about the minimum effective dose of PEG IFN alfa-
2b led the regulatory authorities to request its makers, as a
post-approval commitment, to perform a randomized trial com-
paring 1.5 lg to 1 lg in genotype 1 patients. This was the origi-
nal core project for the IDEAL. Data in favour of efﬁcacy of the
1 lg dose appeared. In an investigator-driven cohort study [4],
PEG IFN alfa-2a at 180 lg was later approved on the basis of
Fried’s trial [5] which reported rates of SVR for HCV genotype 1
comparable to Manns [2] using a narrow range of RBV doses,
from 1000 to 1200 mg/day. Although a further study with PEG
IFN alfa-2a by Hadziyannis [6] clariﬁed that 800 mg of RBV were
not enough, at least for genotype 1, the highest dose assessed was10 vol. 52 j 133–135
Table 1. RCTs and cohort studies with comparative data on PEG IFNs plus ribavirin.
*Ribavirin dose refers principally to genotypes 1 and 4 and is expressed as gm/day. Dose ranging according to body weight.
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genotype 1 with 1000–1200 mg of RBV. Since no claim of superi-
ority, or of non-inferiority, could be made without a direct com-
parison of the two interferons, a comparator arm with PEG IFN
alfa-2a was included in the IDEAL design. A post-marketing
dose-assessment study then became, at least in the eyes of the
physicians and in the nightmares of some marketing experts,
the ﬁnal contest for the best PEG IFN.
A relevant difference found in the IDEAL was the rate of end-
of-treatment response (ETR): 73.9% for PEG IFN alfa-2a and 63.4%
for PEG IFN alfa-2b (mean of both arms). This did not translate
into more SVR for the former, since the relapse rates were,
respectively, 27.8% and 17.8%. To a critical eye, the results of this
study are marred by the difference in the dosing of RBV, both per
schedule and as actually received by the patients. Although the
amount of RBV was regulated by the approved prescribing infor-
mation, the dosing seems inappropriate by current standards. In
fact nowadays, many clinicians (at least in Europe) use both PEG
IFNs with weight-ranging dosing of RBV as the appropriate way
to be sure that patients receive an adequate amount of the latter.
Although the IDEAL is a well constructed study, we must real-
ize some of its limitations. It has been performed in a US popula-
tion, with a high proportion of overweight and obese patients and
20% of those patients were of African American decent. This prev-
alence of difﬁcult-to-treat patients might hence hide minor dif-
ferences in efﬁcacy of the two PEG IFNs by ﬂattening the
response curves. Even more important is the fact that, again
according to the registered schedules, the rules for RBV reduction
in the presence of anemia were different. When Hb level went
below 10 mg/dl, patients on PEG IFN alfa-2a received only one
dose reduction to 600 mg/day, while those on PEG IFN alfa-2a
could have two steps of reduction, each at 200 mg/day. If Hb
failed to recover to levels beyond 8.5 g/dl, RBV was stopped alto-
gether and stepping up of RBV after Hb values had improved was
not allowed in the two arms of the trial. Again, this policy may be
different from everyday practice, where RBV levels are gradually
reduced and readjusted individually. Interestingly, 52% of
patients should have received the same dose of RBV regardless
of the type of PEG IFN; however, amongst the patients actually
being treated, the rate receiving an overall amount of RBV
>13 mg/day was 56% for PEG IFN alfa-2a and 29–33% for PEG
IFN alfa-2b. Since RBV is crucial to obtain viral eradication after
early viral response and ETR, it is difﬁcult to reconcile these data134 Journal of Hepatology 201with the higher relapse rate in the PEG IFN alfa-2a arm. It is sta-
ted that those who had an Hb level below 10 g/dl, albeit requiring
a dose reduction, had a better chance of SVR (48.8% vs. 36.7% of
non-anemic). Anemia was felt to be a surrogate marker of the
actual exposure of RBV and a predictive factor of SVR. Unfortu-
nately, no data are available on the relation between anemia
and SVR split by arms of treatment. Finally, the trial was not
blinded for the type of PEG IFN used. This could have affected
the way some physicians handled treatment.
All available studies that compare the two PEG IFNs, other
than the IDEAL (Table 1 and Refs. [7–11]), show a signiﬁcant
trend towards higher efﬁcacy of PEG IFN alfa-2a, with a range
of difference of SVR between 6 and 13% and an OR between 1.2
and 1.9. This effect is seen both in randomized clinical trials
(RCTs) and in cohort studies. In the two studies where RBV dos-
age is equal or equivalent between the two arms (1 RCT and one
cohort), the difference in favour of PEG IFN alfa-2a is maintained.
Although it is difﬁcult to reconcile this uniform trend with the
IDEAL results, one is left with a feeling that population-related
and dosing-related issues may be more relevant than the type
of drug. In order to determine which PEG IFN is the most effective
for treatment, we will have to await further data based on more
appropriate RBV dosing. However, at a time when triple therapy
with small molecules acting as direct viral inhibitors will soon be
available, one may ask if this issue is even relevant.
We should bear in mind that small differences in outcomes
hyped by the industry, such as the 6.5–7% D pre-ﬁxed as primary
end-point, are of minor practical relevance and are barely percepti-
ble to the clinician. Ultimately, when translating the results of clin-
ical trials into real-lifepractice, it is the tolerability andadherence to
a regimen which matter most. To this aim, the fact that the lesser
dose of PEG IFN alfa-2b is equally effective is probably the most
importantmessage delivered by the IDEAL. Last but not least, atten-
tion should be placed in all kinds of RCTs to a more individualized
dosing of RBV, especially in the difﬁcult-to-treat patient [12], even
beyond the FDA-approved prescribing information.
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